ImmuCell (FRA:IUL) Long-Term Debt: €5.90 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IUL ImmuCell Corp FRA:IUL
55 GF Score
Price €8.30
GF Value €5.66
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell Long-Term Debt?

ImmuCell FRA:IUL +1.22% 55 Long-Term Debt is €5.90 Mil as of Jun. 2026. GuruFocus rates FRA:IUL with a GF Score™ of 55/100 and a GF Value™ of €5.66 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ImmuCell's Long-Term Debt for the quarter that ended in Jun. 2026 was €5.90 Mil.

ImmuCell's quarterly Long-Term Debt declined from Dec. 2025 (€6.40 Mil) to Mar. 2026 (€6.12 Mil) and declined from Mar. 2026 (€6.12 Mil) to Jun. 2026 (€5.90 Mil).

ImmuCell's annual Long-Term Debt declined from Dec. 2023 (€9.67 Mil) to Dec. 2024 (€8.63 Mil) and declined from Dec. 2024 (€8.63 Mil) to Dec. 2025 (€6.40 Mil).

ImmuCell  (FRA:IUL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

ImmuCell Long-Term Debt Related Terms

ImmuCell Long-Term Debt Historical Data

* Premium members only.

The historical data trend for ImmuCell's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell Long-Term Debt Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.37 8.68 9.67 8.63 6.40

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.16 6.73 6.40 6.12 5.90
FRA:IUL
55GF Score
ImmuCell Corp FRA:IUL
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €5.90 Mil mean?
ImmuCell (FRA:IUL) has a Long-Term Debt of €5.90 Mil as of Jun. 2026.
Is ImmuCell's Long-Term Debt too high?
ImmuCell's current Long-Term Debt is €5.90 Mil. Overall, ImmuCell has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Long-Term Debt compare to COYA and ENTX?
ImmuCell's Long-Term Debt of €5.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. ImmuCell's current Long-Term Debt is €5.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (FRA:IUL) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.66, compared to a current price of €8.30 — trading 46.6% above its estimated fair value. The current Long-Term Debt is €5.90 Mil. ImmuCell's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For ImmuCell (FRA:IUL), the current Long-Term Debt is €5.90 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (FRA:IUL) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of €8.30 is trading 46.6% above its estimated GF Value™ of €5.66. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for FRA:IUL:

  • Long-Term Debt: €5.90 Mil
  • GF Value™: €5.66 vs. price of €8.30 (46.6% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:IUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmuCell Business Description

Other Exchanges ICCC:USA
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
55GF Score

Get the complete analysis for FRA:IUL

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.30
Price
€5.66
GF Value